How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

data center infrastructure
AI Is Forcing a Rethink of Data Center Infrastructure at Every Level
December 29, 2025

The data center industry is being redefined by AI’s demand for faster, denser, and more scalable infrastructure. According to McKinsey, average rack power densities have more than doubled in just two years. It went from approximately 8 kW to 17 kW, and is expected to hit 30 kW by 2027. Global data center power demand is projected…

Read More
Emergency department
How Predictive AI Is Helping Hospitals Anticipate Admissions and Optimize Emergency Department Throughput
December 24, 2025

Emergency departments across the U.S. are under unprecedented strain, with overcrowding, staffing shortages, and inpatient bed constraints converging into a throughput crisis. The American Hospital Association reports that hospital capacity and workforce growth have lagged, intensifying delays from arrival to disposition. At the same time, advances in artificial intelligence are moving from experimental to operational—raising…

Read More
Mission
Why Is the Mission of Benchmark So Important
December 23, 2025

As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…

Read More
Benchmark
What Is It Like for You to Be Part of the Benchmark Products Teams Now
December 23, 2025

Being part of the Benchmark Products team today means working at the intersection of precision manufacturing and deeply human collaboration, especially in the high-stakes world of cleanroom and sterility assurance solutions. As the organization grows, employees describe a culture that still feels familial—one where clear communication, personal accountability, and genuine care for customers drive…

Read More